Je was op zoek naar: eritropoetinov (Sloveens - Engels)

odločitev za dajanje rekombinantnih eritropoetinov mora biti
factors that should be considered

v literaturi najdemo nasprotujoča si poročila o vlogi eritropoetinov pri pospeševanju proliferacije tumorjev.
there are conflicting reports in the literature regarding whether erythropoietins may play a major role as tumour proliferators.

podatki iz kliničnih študij z zdravilom retacrit so v skladu z varnostnim profilom drugih eritropoetinov z dovoljenjem za promet.
data from clinical studies with retacrit are in line with the safety profile of other authorized erythropoietins.

odločitev za uporabo rekombinantnih eritropoetinov mora temeljiti na oceni koristi in tveganja in mora biti sprejeta v sodelovanju z bolnikom, upoštevaje do
in this assessment should include the type of tumour and its stage; the degree of anaemia; life- in

odločitev za dajanje rekombinantnih eritropoetinov mora biti sprejeta v sodelovanju z bolnikom, temeljiti pa mora na oceni koristi in tveganja ob upoštevanju specifičnih kliničnih okoliščin.
the decision to administer recombinant erythropoietins should be based on a benefit-risk assessment with the participation of the individual patient, which should take into account the specific clinical context.

odločitev za uporabo rekombinantnih eritropoetinov mora temeljiti na oceni koristi in tveganja in mora biti sprejeta v sodelovanju z bolnikom, upoštevaje posameznikove specifične klinične okoliščine.
the decision to administer recombinant erythropoietins should be based on a benefit-risk assessment with the participation of the individual patient, which should take into account the specific clinical context.